Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

<p>Table S1 shows expression of RBPs in an RNA-sequencing data set of human bone marrow hematopoietic stem and progenitor subpopulations.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Ana Vujovic (15207479) (author)
Kolejni autorzy:	Laura de Rooij (15207482) (author), Ava Keyvani Chahi (15207485) (author), He Tian Chen (15207488) (author), Brian A. Yee (15207491) (author), Sampath K. Loganathan (15121740) (author), Lina Liu (15207494) (author), Derek C.H. Chan (15207497) (author), Amanda Tajik (15207500) (author), Emily Tsao (15207503) (author), Steven Moreira (14937143) (author), Pratik Joshi (15207506) (author), Joshua Xu (15207509) (author), Nicholas Wong (15207512) (author), Zaldy Balde (15207515) (author), Soheil Jahangiri (15207518) (author), Sasan Zandi (15207521) (author), Stefan Aigner (15207524) (author), John E. Dick (14937554) (author), Mark D. Minden (14961936) (author), Daniel Schramek (15121764) (author), Gene W. Yeo (15207527) (author), Kristin J. Hope (15207530) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors Oncogenes Preclinical Models Xenograft models Small Molecule Agents Stem Cell Biology Cancer stem cells Hematopoiesis
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
od: Ana Vujovic (15207479)
Wydane: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
od: Smruthy Sivakumar (15053536)
Wydane: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Wydane: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
od: Yuanqing Ma (15052437)
Wydane: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Wydane: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Wydane: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Wydane: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Wydane: (2025)

Supplementary Tables S3-5 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
od: Nicole Dressel (16918215)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qos6ckc3slt1o8ikff65865k48